Insider Selling Continues to Shake Up Mirum’s Share Price

Insider Selling Continues to Shake Up Mirum’s Share Price

Mirum Pharmaceuticals Inc. has recently filed a Form 4 revealing that Chief Financial Officer Eric Bjerkholt sold 6,001 shares of the company’s common stock at an average price of $99.90. The transaction, executed under a Rule 10b5‑1 plan, occurred just after the market price had dipped to $98.97. Although the volume represents a modest portion of the company’s market capitalization of $6.54 billion, it is part of a broader pattern of frequent insider liquidations that has been on investors’ radar for months.

Insider Activity and Its Implications

The cumulative insider activity over the past six months suggests a potential short‑term bearish sentiment. Executives—including CEO Christopher Peetz—have been liquidating significant positions, reducing the insider holdings from a peak of 57,075 shares in March to 36,355 after Bjerkholt’s latest sale. This erosion of ownership stakes may raise concerns about management’s confidence in the company’s near‑term prospects, especially as the share price has declined 16.86 % over the last month.

Despite the recent selling, insiders still maintain substantial positions—over 36 000 shares—indicating that they believe in Mirum’s long‑term value, particularly in its therapeutic pipeline for cholestatic liver disease. Analysts should monitor whether the selling trend persists or stabilises; continued outflows could depress the stock further, while a slowdown might support a rebound.

Bjerkholt’s Trading Profile

Since March 2026, Bjerkholt has executed 18 transactions, comprising 12 sales and six purchases. His most aggressive sale was 7,287 shares at $91.98 in mid‑March, followed by smaller sales at higher prices in July and August. He has also bought shares—most notably 13,334 shares in March at an undisclosed price and 2,393 shares in early June for $26.49, an unusually low price that suggests a strategic acquisition of undervalued shares. The mix of sales and purchases indicates that Bjerkholt is managing his holdings to balance liquidity needs while maintaining a long‑term stake. The use of a Rule 10b5‑1 plan for the August sale underscores a preference for pre‑arranged, rule‑compliant selling rather than opportunistic trades.

Market Context and Outlook

Mirum’s share price has shown a mixed trajectory: a 52‑week high of $130, a year‑high of $98.23, and a steep yearly decline of 52.66 %. The company’s price‑earnings ratio of –6.14 reflects investors’ pricing of negative earnings expectations, largely due to the nascent pipeline of therapies. Social media buzz remains neutral, and sentiment scores are flat, underscoring the high‑risk, high‑potential nature of the investment.

Insider selling, while a cautionary sign, does not necessarily predict a downward trajectory, particularly if the sales are part of a broader liquidity strategy and insiders retain sizeable positions. Investors should continue to monitor upcoming regulatory filings, clinical trial updates, and shifts in insider ownership to gauge whether the stock is primed for a rebound or further consolidation.

This article is intended for informational purposes only and does not constitute investment advice.